Defence Therapeutics (TSE:DTC)
:DTC
DTC Stock Chart & Stats
C$0.78
-C$0.03(-4.41%)
At close: 4:00 PM EST
C$0.78
-C$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeC$0.52 - C$1.08
Previous CloseN/A
Volume0.00
Average Volume (3M)68.27K
Market Cap
C$29.83M
Enterprise ValueC$30.37M
Total Cash (Recent Filing)C$947.35K
Total Debt (Recent Filing)C$1.49M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding57,369,970
10 Day Avg. Volume109,889
30 Day Avg. Volume68,269
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformThe Accum® platform is a durable scientific asset: improving intracellular delivery and potency across biologic modalities can create sustained differentiation. A broadly applicable delivery tech supports multiple programs, enables partnership/licensing opportunities, and reduces single-program binary risk over time.
Diversified Early-Stage PipelineA pipeline spanning oncology and infectious disease plus modalities like immunotherapy and ADCs spreads scientific and market risk. Platform applicability across indications increases the chance that at least one program progresses, supporting long-term option value despite precommercial status.
Improving Loss ProfileMaterial reduction in annual losses and improved free cash flow versus prior periods indicate management has cut burn and improved operating efficiency. These trends extend runway and reduce near-term financing frequency, raising the probability of completing key R&D milestones.
Bears Say
No Commercial RevenueThe company has no product revenue and persistent negative gross profit, meaning it remains fully precommercial. Long-term viability therefore depends on successful clinical progress or partnerships; absence of revenue sustains financing dependency and limits reinvestment without dilution.
Balance-Sheet WeaknessNegative equity and meaningful debt relative to modest assets constrain financial flexibility. This elevates refinancing and dilution risk, can raise cost of capital, and may limit the company’s ability to fund trials or strike favorable partnerships without dilutive or expensive financing.
Ongoing Cash BurnSustained negative operating cash flow (~-4.9M TTM) shows continued cash burn typical of early biotech. Reliance on external funding is structural; if financing markets tighten or milestones slip, program timelines and clinical development pace could be delayed, harming long-term prospects.
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was C$0.52 and its highest was C$1.08 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is C$29.83M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is May 22, 2026 which is in 47 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on Feb 20, 2026. The company reported -C$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.028.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 57,369,970 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -C$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.154%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in TSE:DTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―